Centre Hospitalier de la Région d'Annecy Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2012
NCT01522534
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Centre Hospitalier de la Région d'Annecy

Active Ingredients

Drugs in Phase 3 Trials (2)

mepivacaine (carbocaine) (1 trial)

morphine (1 trial)

Drugs in Phase 2 Trials (2)

denosumab (prolia) (1 trial)

nivolumab (opdivo) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bone Marrow Diseases (Phase 2)

Bone Neoplasms (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Emergencies (Phase 3)

Neoplasm Metastasis (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 4